Literature DB >> 1425108

Increased plasma endothelin in NIDDM patients with retinopathy.

M Kawamura1, H Ohgawara, M Naruse, N Suzuki, N Iwasaki, K Naruse, S Hori, H Demura, Y Omori.   

Abstract

OBJECTIVE: To elucidate the significance of ET in diabetic microvascular disease. RESEARCH DESIGN AND METHODS: We determined plasma levels of ir-ET-1 in 25 NIDDM patients without hypertension and/or renal dysfunction.
RESULTS: The plasma levels of ir-ET-1 in NIDDM patients with simple (n = 8) and proliferative (n = 8) retinopathy were 0.58 +/- 0.04 pM and 0.60 +/- 0.04 pM, respectively, which were significantly higher than those in normal, nondiabetic subjects (0.24 +/- 0.02 pM [n = 31]) and NIDDM patients without retinopathy (0.30 +/- 0.05 pM [n = 9]).
CONCLUSIONS: These results suggest that plasma ET-1 is related to diabetic microvascular disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425108     DOI: 10.2337/diacare.15.10.1396

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  14 in total

Review 1.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  Plasma endothelin-1 levels depress optic nerve head circulation detected during the glucose tolerance test.

Authors:  Teruyo Kida; Tetsuya Sugiyama; Hidehiro Oku; Seiyo Harino; Tsunehiko Ikeda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-17       Impact factor: 3.117

Review 3.  Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes.

Authors:  M Porta
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

4.  Increased plasma endothelin in diabetes: an atherosclerosis marker?

Authors:  R Patiño; J Ibarra; A Molino; R Fernandez-Durango; J Moya; A Fernandez-Cruz
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

5.  Effect of pan-retinal laser photocoagulation on plasma VEGF, endothelin-1 and nitric oxide in PDR.

Authors:  Tarek Ahmed Mohamed; Sahar El-Deek Mohamed
Journal:  Int J Ophthalmol       Date:  2010-03-18       Impact factor: 1.779

6.  Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients.

Authors:  F Perfetto; R Tarquini; V de Leonardis; A Piluso; V Lombardi; B Tarquini
Journal:  Acta Diabetol       Date:  1995-12       Impact factor: 4.280

7.  Endothelin-1 inhibits TNF alpha-induced iNOS expression in 3T3-F442A adipocytes.

Authors:  Christelle Mérial-Kieny; Michel Lonchampt; Francis Cogé; Patrick Verwaerde; Jean-Pierre Galizzi; Jean A Boutin; Max Lafontan; Nigel Levens; Jean Galitzky; Michel Félétou
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 8.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

9.  Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat.

Authors:  S Bardal; D Misurski; X Qiu; K Desai; J R McNeill
Journal:  Diabetologia       Date:  2006-02-23       Impact factor: 10.122

10.  Endothelin-1 immunoreactivity in plasma is elevated in HIV-1 infected patients with retinal microangiopathic syndrome.

Authors:  B Rolinski; S A Geier; I Sadri; V Klauss; J R Bogner; H Ehrenreich; F D Goebel
Journal:  Clin Investig       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.